TesoRx Pharma Revenue and Competitors
Estimated Revenue & Valuation
- TesoRx Pharma's estimated annual revenue is currently $620k per year.
- TesoRx Pharma's estimated revenue per employee is $155,000
Employee Data
- TesoRx Pharma has 4 Employees.
- TesoRx Pharma grew their employee count by -20% last year.
TesoRx Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
TesoRx Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is TesoRx Pharma?
TesoRx is a privately held pharmaceutical company developing a first-in-class unmodified oral testosterone for androgen deficiency. It is in the process of completing a phase two clinical study and is on track to commence dosing for phase three by early 2014. The US market for topical, transdermal and injectible testosterone formulations alone is currently estimated at $2.1 Billion with prescriptions having grown 90% over five years. Analysts project that the entire testosterone market is expected to hit $5 billion by 2017. A safe and effective oral treatment regimen remains the main unmet need and studies suggest that it could cannibalize more than 70% of existing treatments once introduced into the market.
keywords:N/AN/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.3M | 4 | 0% | N/A |
#2 | $0.4M | 4 | -20% | N/A |
#3 | $0.3M | 4 | N/A | N/A |
#4 | $0.3M | 4 | -20% | N/A |
#5 | $0.3M | 4 | N/A | N/A |